Synapse - VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup

VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup Meeting Abstract

Authors:	Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; Landau, H. J.; Scordo, M.; Chung, D. J.; Shah, G.; Lahoud, O. B.; Derkach, A.; Giralt, S. A.; Landgren, O.
Abstract Title:	VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607547203001
DOI:	10.1182/blood-2020-141988
PROVIDER:	wos
Notes:	Meeting Abstract: 37 -- Source: Wos